Hardman & Co Research / GB00B5SGVL29
10.04.2024 - 08:15:07Hardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth
| Hardman & Co Research Hardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth 10-Apr-2024 / 07:15 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue processing, manufacturing capacity and strong commercial partners, together with its “4S” strategy, has generated six consecutive reporting periods of strong growth, with TRX turning EBITDA-positive in 2023. New growth in 2024 will deliver a fully profitable, cash-generative, group. The cash will be invested to expand capacity even further through Phase 2, starting in 2025. Please click on the link below for the full report: https://hardmanandco.com/research/corporate-research/trx_six-consecutive-periods-of-20-growth/ If you are interested in meeting the company, you can register your interest by clicking on the above link.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. |
